164926-91-4

Usage

Uses

Used in Pharmaceutical Industry:
1-Piperazineethanethioamide,4-methylis used as a key intermediate in the synthesis of various pharmaceutical products for its versatile chemical structure and potential therapeutic effects.
Used in Cancer Treatment Research:
In the field of oncology, 1-Piperazineethanethioamide,4-methylis being explored as a potential therapeutic agent for the treatment of various types of cancer. Its role in this application is attributed to its chemical properties that may allow it to interact with biological targets relevant to cancer progression and management.
Used in Psychiatric Disorder Treatment Research:
1-Piperazineethanethioamide,4-methylis also being investigated for its potential use in the treatment of psychiatric disorders. 1-Piperazineethanethioamide,4-methyl-'s structure, which includes a piperazine ring, is a common feature in many psychotropic medications, suggesting it may have relevant pharmacological activity in this area.

InChI:InChI=1/C7H15N3S/c1-9-2-4-10(5-3-9)6-7(8)11/h2-6H2,1H3,(H2,8,11)

Upstream product

• 83808-21-3 2-(4-methyl-1-piperazinyl)acetamide 
• 874-77-1 2-(4-methylpiperazin-1-yl)acetonitrile 
• 109-01-3 1-methyl-piperazine 

Relevant academic research and scientific papers

Receptor-Type Kinase Modulators and Methods of Use

The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases

Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K

We have prepared a series of achiral aminoacetonitriles, bearing tri-ring benzamide moieties and an aminocyclohexanecarboxylate residue at P2. This combination of binding elements resulted in sub-250 pM, reversible, selective, and orally bioavailable cathepsin K inhibitors. Lead compounds displayed single digit nanomolar inhibition in vitro (of rabbit osteoclast-mediated degradation of bovine bone). The best compound in this series, 39n (CRA-013783/L-006235), was orally bioavailable in rats, with a terminal half-life of over 3 h. 39n was dosed orally in ovariectomized rhesus monkeys once per day for 7 days. Collagen breakdown products were reduced by up to 76% dose-dependently. Plasma concentrations of 39n above the bone resorption IC50 after 24 h indicated a correlation between functional cellular and in vivo assays. Inhibition of collagen breakdown by cathepsin K inhibitors suggests this mechanism of action may be useful in osteoporosis and other indications involving bone resorption.

Conformationally restricted thiazole derivatives as novel class of 5-HT3 receptor ligands

A new series of tricyclic derivatives of 2-methyl-naphtho[1,2-d] thiazole were synthesized in order to investigate the effects of the conformational restriction of bicyclic thiazole derivatives previously reported on the 5-HT3 receptor affinity. The basic moiety in these compounds is represented by the terminal nitrogen of N-methyl-piperazine or N-methyl-piperidine ring-linked at 2-methyl. All the tricyclic derivatives have a significant 5-HT3 receptor binding affinity and the terminal piperazine ring is more suitable than piperidine one.